Literature DB >> 8691457

Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone.

M C Liu1, T S Lin, J G Cory, A H Cory, A C Sartorelli.   

Abstract

A series of 3- and 5-alkylamino derivatives, as well as other structurally modified analogues of pyridine-2-carboxaldehyde thiosemicarbazone, have been synthesized and evaluated as inhibitors of CDP reductase activity and for their cytotoxicity in vitro and antineoplastic activity in vivo against the L1210 leukemia. Alkylation of 3- and 5-amino-2-(1,3-dioxolan-2-yl)pyridines (1, 2) resulted in corresponding 3-methylamino, 5-methylamino, 3-allylamino, 5-ethylamino, 5-allylamino, 5-propylamino, and 5-butylamino derivatives (5, 6, and 11-15), which were then condensed with thiosemicarbazide to yield the respective thiosemicarbazones (7, 8, and 16-20). Oxidation of 3,5-dinitro-2-methylpyridine (21) with selenium dioxide, followed by treatment with ethylene glycol and p-toluenesulfonic acid, produced the cyclic ethylene acetal, 23. Oxidation of 2-(1,3-dioxolan-2-yl)-4-methyl-5-nitropyridine (26) with selenium dioxide, followed by sequential treatment with sodium borohydride, methanesulfonyl chloride, and morpholine afforded the morpholinomethyl derivative 30. Catalytic hydrogenation of 23 and 30 with Pd/C yielded the corresponding amino derivatives 24 and 31. Catalytic hydrogenation of 5-cyano-2-methylpyridine (33) with Raney nickel, followed by treatment with acetic anhydride, gave the amide derivative 35. N-Oxidation of 35, followed by rearrangement with acetic anhydride, produced the acetate derivative, 5-[(acetylamino)methyl]-2-(acetoxymethyl)pyridine (37). Repetition of the N-oxidation and rearrangement procedures with compound 37 yielded the diacetate derivative 39. Condensation of compounds 24, 31, and 39 with thiosemicarbazide afforded the respective 3,5-diaminopyridine-, 4-(4-morpholinylmethyl)-5-aminopyridine-, and 5-(aminomethyl)pyridine-2-carboxaldehyde thiosemicarbazones (25, 32, and 40). The most biologically active compounds synthesized were the 5-(methylamino)-, 5-(ethylamino)-, and 5-(allylamino)pyridine-2-carboxaldehyde thiosemicarbazones (8, 17, and 18), which were potent inhibitors of ribonucleotide reductase activity with corresponding IC50 values of 1.3, 1.0, and 1.4 microM and which produced significant prolongation of the survival time of L1210 leukemia-bearing mice, with corresponding optimum % T/C values of 223, 204, and 215 being obtained when administered twice daily for six consecutive days at dosages of 60, 80, and 80 mg/kg, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691457     DOI: 10.1021/jm9600454

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

2.  Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Authors:  Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-28       Impact factor: 3.333

Review 3.  Porphyrins as ligands for 64copper: background and trends.

Authors:  Edgar Aguilar-Ortíz; Amir R Jalilian; Miguel A Ávila-Rodríguez
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

4.  Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.

Authors:  Daniel Sun; Juno Van Valkenburgh; Sheba Plamthottam; Jeffrey Valenzuela; Bastian Ruehle; Dalton Steele; Soumya Poddar; Maxim Marshalik; Selena Hernandez; Caius Gabriel Radu; Jeffrey I Zink
Journal:  J Biol Inorg Chem       Date:  2019-06-27       Impact factor: 3.358

5.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; B Douglas Smith; Ivana Gojo; Steven D Gore; Mark J Levis; Hetty E Carraway; Jacqueline M Greer; S Percy Ivy; Keith W Pratz; Michael A McDevitt
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

6.  Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity.

Authors:  Thomas J F Nieland; Jared T Shaw; Firoz A Jaipuri; Jay L Duffner; Angela N Koehler; Sotirios Banakos; Vassilis I Zannis; Tomas Kirchhausen; Monty Krieger
Journal:  Biochemistry       Date:  2007-12-08       Impact factor: 3.162

7.  Synthesis and characterization of new copper thiosemicarbazone complexes with an ONNS quadridentate system: cell growth inhibition, S-phase cell cycle arrest and proapoptotic activities on cisplatin-resistant neuroblastoma cells.

Authors:  Haiyuan Zhang; Ronald Thomas; David Oupicky; Fangyu Peng
Journal:  J Biol Inorg Chem       Date:  2007-10-02       Impact factor: 3.358

8.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Authors:  Judith E Karp; Francis J Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

9.  ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

Authors:  Thuc M Le; Soumya Poddar; Joseph R Capri; Evan R Abt; Woosuk Kim; Liu Wei; Nhu T Uong; Chloe M Cheng; Daniel Braas; Mina Nikanjam; Peter Rix; Daria Merkurjev; Jesse Zaretsky; Harley I Kornblum; Antoni Ribas; Harvey R Herschman; Julian Whitelegge; Kym F Faull; Timothy R Donahue; Johannes Czernin; Caius G Radu
Journal:  Nat Commun       Date:  2017-08-14       Impact factor: 14.919

10.  Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention.

Authors:  Christian R Kowol; Walter Miklos; Sarah Pfaff; Sonja Hager; Sebastian Kallus; Karla Pelivan; Mario Kubanik; Éva A Enyedy; Walter Berger; Petra Heffeter; Bernhard K Keppler
Journal:  J Med Chem       Date:  2016-07-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.